The impact of the new ESTRO-ACROP target volume delineation guidelines for postmastectomy radiotherapy after implant-based breast reconstruction on breast complications

Jung Bin Park, Bum-Sup Jang, Ji Hyun Chang, Jin Ho Kim, Chang Heon Choi, Ki Young Hong, Ung Sik Jin, Hak Chang, Yujin Myung, Jae Hoon Jeong, C. Heo, In Ah Kim, Kyung Hwan Shin
{"title":"The impact of the new ESTRO-ACROP target volume delineation guidelines for postmastectomy radiotherapy after implant-based breast reconstruction on breast complications","authors":"Jung Bin Park, Bum-Sup Jang, Ji Hyun Chang, Jin Ho Kim, Chang Heon Choi, Ki Young Hong, Ung Sik Jin, Hak Chang, Yujin Myung, Jae Hoon Jeong, C. Heo, In Ah Kim, Kyung Hwan Shin","doi":"10.3389/fonc.2024.1373434","DOIUrl":null,"url":null,"abstract":"The European Society for Radiotherapy and Oncology–Advisory Committee in Radiation Oncology Practice (ESTRO-ACROP) updated a new target volume delineation guideline for postmastectomy radiotherapy (PMRT) after implant-based reconstruction. This study aimed to evaluate the impact on breast complications with the new guideline compared to the conventional guidelines. In total, 308 patients who underwent PMRT after tissue expander or permanent implant insertion from 2016 to 2021 were included; 184 received PMRT by the new ESTRO-ACROP target delineation (ESTRO-T), and 124 by conventional target delineation (CONV-T). The endpoints were major breast complications (infection, necrosis, dehiscence, capsular contracture, animation deformity, and rupture) requiring re-operation or re-hospitalization and any grade ≥2 breast complications. With a median follow-up of 36.4 months, the cumulative incidence rates of major breast complications at 1, 2, and 3 years were 6.6%, 10.3%, and 12.6% in the ESTRO-T group, and 9.7%, 15.4%, and 16.3% in the CONV-T group; it did not show a significant difference between the groups (p = 0.56). In multivariable analyses, target delineation is not associated with the major complications (sHR = 0.87; p = 0.77). There was no significant difference in any breast complications (3-year incidence, 18.9% vs. 23.3%, respectively; p = 0.56). Symptomatic RT-induced pneumonitis was developed in six (3.2%) and three (2.4%) patients, respectively. One local recurrence occurred in the ESTRO-T group, which was within the ESTRO-target volume. The new ESTRO-ACROP target volume guideline did not demonstrate significant differences in major or any breast complications, although it showed a tendency of reduced complication risks. As the dosimetric benefits of normal organs and comparable oncologic outcomes have been reported, further analyses with long-term follow-up are necessary to evaluate whether it could be connected to better clinical outcomes.","PeriodicalId":507440,"journal":{"name":"Frontiers in Oncology","volume":"42 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1373434","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The European Society for Radiotherapy and Oncology–Advisory Committee in Radiation Oncology Practice (ESTRO-ACROP) updated a new target volume delineation guideline for postmastectomy radiotherapy (PMRT) after implant-based reconstruction. This study aimed to evaluate the impact on breast complications with the new guideline compared to the conventional guidelines. In total, 308 patients who underwent PMRT after tissue expander or permanent implant insertion from 2016 to 2021 were included; 184 received PMRT by the new ESTRO-ACROP target delineation (ESTRO-T), and 124 by conventional target delineation (CONV-T). The endpoints were major breast complications (infection, necrosis, dehiscence, capsular contracture, animation deformity, and rupture) requiring re-operation or re-hospitalization and any grade ≥2 breast complications. With a median follow-up of 36.4 months, the cumulative incidence rates of major breast complications at 1, 2, and 3 years were 6.6%, 10.3%, and 12.6% in the ESTRO-T group, and 9.7%, 15.4%, and 16.3% in the CONV-T group; it did not show a significant difference between the groups (p = 0.56). In multivariable analyses, target delineation is not associated with the major complications (sHR = 0.87; p = 0.77). There was no significant difference in any breast complications (3-year incidence, 18.9% vs. 23.3%, respectively; p = 0.56). Symptomatic RT-induced pneumonitis was developed in six (3.2%) and three (2.4%) patients, respectively. One local recurrence occurred in the ESTRO-T group, which was within the ESTRO-target volume. The new ESTRO-ACROP target volume guideline did not demonstrate significant differences in major or any breast complications, although it showed a tendency of reduced complication risks. As the dosimetric benefits of normal organs and comparable oncologic outcomes have been reported, further analyses with long-term follow-up are necessary to evaluate whether it could be connected to better clinical outcomes.
ESTRO-ACROP 关于植入物乳房再造术后放疗的新靶区划分指南对乳房并发症的影响
欧洲放射治疗与肿瘤学会-放射肿瘤实践咨询委员会(ESTRO-ACROP)更新了植入物重建后乳房切除术后放射治疗(PMRT)的新靶体积划定指南。本研究旨在评估新指南与传统指南相比对乳腺并发症的影响。研究共纳入了308名在2016年至2021年期间接受组织扩张器或永久性假体植入术后PMRT治疗的患者;其中184人接受了ESTRO-ACROP新靶点划定(ESTRO-T)的PMRT治疗,124人接受了传统靶点划定(CONV-T)的PMRT治疗。终点是需要再次手术或再次住院的主要乳房并发症(感染、坏死、开裂、囊挛、动画畸形和破裂)以及任何≥2级的乳房并发症。中位随访时间为36.4个月,ESTRO-T组1年、2年和3年的主要乳房并发症累积发生率分别为6.6%、10.3%和12.6%,CONV-T组分别为9.7%、15.4%和16.3%,组间差异不显著(P = 0.56)。在多变量分析中,目标划定与主要并发症无关(sHR = 0.87;p = 0.77)。乳腺并发症也无明显差异(3 年发生率分别为 18.9% 和 23.3%;p = 0.56)。分别有6名(3.2%)和3名(2.4%)患者出现了RT诱发的症状性肺炎。ESTRO-T组有1例局部复发,发生在ESTRO靶体积内。新的 ESTRO-ACROP 目标容积指南虽然显示出并发症风险降低的趋势,但在主要或任何乳腺并发症方面并未显示出显著差异。由于有报道称正常器官的剂量学优势和可比的肿瘤结果,因此有必要进行进一步的长期随访分析,以评估其是否与更好的临床结果相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信